US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
C4 Therapeutics Inc. shares have tumbled to a 52-week low, with the stock price touching $3.24, marking a significant downturn for the biotech firm. With a beta of 2.96 and a current ratio of 6.31, InvestingPro data shows the company maintains strong liquidity despite its volatile trading pattern. Over the past year, the company has seen its stock value erode by 51.33%, reflecting investor concerns and broader market trends that have weighed heavily on the sector. This latest price level underscores the challenges C4 Therapeutics faces as it navigates through a period of heightened scrutiny and shifting investor sentiment within the biopharmaceutical industry. Analyst price targets range from $4 to $50, suggesting significant potential upside according to InvestingPro analysis, with 8 additional key insights available to subscribers.
In other recent news, C4 Therapeutics has made significant strides in its 2025 clinical trials, particularly with the advancement of its protein degradation therapies, cemsidomide and CFT1946. The firm has completed the Phase 1 dose escalation for cemsidomide, with data expected in the latter half of 2025, and plans for further clinical development in multiple myeloma. Concurrently, CFT1946 is progressing through its Phase 1 trial, with results anticipated in the second half of the year.
In the realm of personnel, C4 Therapeutics has added industry veteran Steve Hoerter to its Board of Directors, a move that aligns with the company’s strategic growth plans. Hoerter brings over three decades of experience in oncology commercialization, having held key roles at Deciphera Pharmaceuticals (NASDAQ:DCPH) and Agios Pharmaceuticals.
Analysts from Jefferies and Stifel have maintained a positive outlook on C4 Therapeutics, particularly following promising data from early-stage trials of its cancer drug, cemsidomide. The drug showed a dose-dependent response in patients with relapsed or refractory multiple myeloma and Non-Hodgkin’s Lymphoma, fostering optimism for its potential efficacy and safety.
These recent developments underscore C4 Therapeutics’ commitment to advancing its clinical programs and enhancing its leadership team to support growth. The company’s current financial resources are expected to fund operations into 2027, allowing it to continue its critical work in oncology and non-oncology targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.